ISN NEXUS SYMPOSIUM ON COMPLEMENT RELATED KIDNEY DISEASES: CLASSIFICATION, GENETICS AND TREATMENT

Bergamo (Italy), September ..., 2015

DAY 1

12.00 – 13.3	30	Registration and light lunch
13.30 –14.3	0	Introductory remarks and State of the art Lecture:
		 Giuseppe Remuzzi Italy
Session I Atypical he	molytic ເ	uremic syndrome (aHUS)
14.30 – 15.0	00	CFH abnormalities: mutations, rearrangements, deletions and auto- antibodies Timothy H.J. Goodship United Kingdom
15.00 – 15.3	30	Mutations in other complement genes and DGKE Veronique Fremeaux-Bacchi France
15.30 – 16.0	00	Podocyte injury as a risk and a complication of aHUS Marina Noris Italy
16.00 – 16.3	30	Coffee break
16.30 – 17.0	00	Outcome of aHUS: what has changed in the last years? Christoph Licht Canada
17.00 – 17.3	30	Emerging complement biomarkers for an individualized therapy Miriam Galbusera Italy
17.30 – 18.0	00	Kidney and kidney/liver transplantation in aHUS Piero Ruggenenti

Italy

DAY 2

Session II Immune-complex-mediated MPGN (IC-MPGN) and C3 glomerulopathy (C3G)

08.30 – 09.00	Classification: new thinking of an old entity Vivette D. D'Agati USA
09.00 – 09.30	Gene mutations and genomic rearrangements Santiago Rodriguez de Cordoba Spain
09.30 – 10.00	Auto-antibodies and C3Nef Peter F. Zipfel Germany
10.00 – 10.30	From animals to humans (and vice versa) Matthew C. Pickering United Kingdom
10.30 – 11.00	Coffee break
11.00 – 11.30	Natural history and outcome predictors
11.30 – 12.00	Eculizumab treatment: who may benefit?
12.00 – 12.30	New therapeutic approaches and perspectives Richard J. H. Smith USA
12.30 – 14.30	Lunch and Poster presentation

Session III Workshop/Discussion Groups

14.30 - 16.30

Workshop 1 aHUS - Genetics and Classification Chair: Co-chair:

Co-chair:

Workshop 2 aHUS - Treatment with complement inhibitors: who, when and how long?

Chair: Co-chair: Co-chair:

Workshop 3 IC-MPGN/C3G - Pathogenesis and Classification

Chair: Co-chair: Co-chair:

 $Workshop\ 4\quad IC\text{-}MPGN/C3G\ Treatment:\ Perspectives\ of\ studies\ with\ complement\ inhibitors\ and$

criteria for enrollment

Chair: Co-chair: Co-chair:

16.30 – 17.00 Coffee break

Session IV
Oral presentations

17.00 - 18.00

DAY 3

8.30 – 9.30 Workshop Reports

Session V

Meet the doctors - An open discussion between patients and doctors

9.30 – 11.00	Experts will explain what is aHUS and how it has been and will be treated
11.00 – 11.30	Coffee break
11.30 – 13.00	Experts will explain what are IC-MPGN/C3G and how they have been and will be treated
13.00 – 13.30	Conclusions
13.30	Light lunch